Truist Financial reaffirms its buy rating for
IQVIA Holdings (IQV) that also sees an upgrade from
HSBC and
Leerink Partners.
Gilliland Jeter Wealth Management LLC and
Eastern Bank reduce their
IQV stakes while
Shell Asset Management Co and
Mirae Asset Global Investments Co. Ltd. increased their holdings.
IQV's intrinsic value is reportedly 52% higher than its share price, sparking further interest among value and growth investors. An expanded
GSK partnership could enhance
IQV's competitive edge. Various institutional investors, such as
Armstrong Fleming & Moore Inc,
Marks Group Wealth Management Inc and
HB Wealth Management LLC among others, strengthen their position in
IQV. A partnership with
Flagship Pioneering aims to speed up the growth of breakthrough life sciences companies.
IQV's Q2 2025 earnings revealed record revenue figures fueled by strategic AI. New partnerships are in play with
Kexing Biopharm to further drug development.
IQV plans to announce the third-quarter 2025 results on October 28, 2025. The company's stock performance beats other health tech stocks, with recent earnings pushing the stock up 25%.
IQV's new CFO appointment sees Michael Fedock replacing Ron Bruehlman. The brace for a future AI research partnership could drive further growth.
Iqvia Holdings IQV News Analytics from Thu, 13 Mar 2025 07:00:00 GMT to Sat, 11 Oct 2025 11:42:00 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 5
